GLABF (Gemina Laboratories) Debt-to-EBITDA : -0.18 (As of Oct. 2025)

What is Gemina Laboratories Debt-to-EBITDA?

Gemina Laboratories GLABF -27.59% Debt-to-EBITDA is -0.18 as of Oct. 2025. The stock has 2 warning signs investors should review.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gemina Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2025 was $0.17 Mil. Gemina Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2025 was $0.00 Mil. Gemina Laboratories's annualized EBITDA for the quarter that ended in Oct. 2025 was $-0.95 Mil. Gemina Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Oct. 2025 was -0.18.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Gemina Laboratories's Debt-to-EBITDA or its related term are showing as below:

GLABF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.34 Med: -0.07 Max: -0.01
Current: -0.09

During the past 5 years, the highest Debt-to-EBITDA Ratio of Gemina Laboratories was -0.01. The lowest was -0.34. And the median was -0.07.

GLABF's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.14 vs GLABF: -0.09

Gemina Laboratories (OTCPK:GLABF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Gemina Laboratories Debt-to-EBITDA Related Terms

Gemina Laboratories Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Debt-to-EBITDA Chart

Gemina Laboratories Annual Data

Trend

Jan21

Jan22

Jan23

Jan24

Jan25

Debt-to-EBITDA

N/A

-0.01

-0.04

-0.10

-0.34

Gemina Laboratories Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.46	-0.24	-0.09	-0.15	-0.18

GLABF vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Gemina Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Debt-to-EBITDA falls into.

Save Embed

Gemina Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gemina Laboratories's Debt-to-EBITDA for the fiscal year that ended in Jan. 2025 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.763	+	0.122)	/	-2.638
	=	-0.34

Gemina Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Oct. 2025 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.172	+	0)	/	-0.948
	=	-0.18

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Oct. 2025) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of -0.18 mean?

Gemina Laboratories (GLABF) has a Debt-to-EBITDA of -0.18 as of Oct. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gemina Laboratories.

Is Gemina Laboratories' Debt-to-EBITDA too high?

Gemina Laboratories' current Debt-to-EBITDA is -0.18.

How does Gemina Laboratories' Debt-to-EBITDA compare to VRTX and REGN?

Gemina Laboratories' Debt-to-EBITDA of -0.18 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Biotechnology company?

The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gemina Laboratories. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gemina Laboratories's current Debt-to-EBITDA is -0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Gemina Laboratories stock overvalued right now?

Gemina Laboratories (GLABF) has a current Debt-to-EBITDA of -0.18. The current Debt-to-EBITDA is -0.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Debt-to-EBITDA is -0.18 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:AGN TSXV:RKV TSX:APLI XCNQ:NURL TSXV:IBO XCNQ:ASEP XCNQ:HEAL TSXV:WAVE TSXV:XRTX XCNQ:BIOV VRTX REGN XBRU:UCB XKRX:207940 ASX:CSL XBRU:ARGX ALNY ONC INSM XKRX:068270

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8

Website https://www.geminalabs.com

Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.